Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

AI-Assisted Endoscopy for Upper Aerodigestive Tract Lesions (H&NANCE)

12 maggio 2026 aggiornato da: Istituto Italiano di Tecnologia

Head&Neck Application of Novel Computer-assisted Endoscopy

This is a prospective observational clinical study designed to evaluate the performance of artificial intelligence (AI) algorithms applied to upper aerodigestive tract (UADT) video-endoscopy. The study assesses three main tasks: lesion detection (localization), classification (benign vs malignant), and segmentation of tumor margins.

AI algorithms will be applied to endoscopic video data acquired during routine clinical practice without influencing clinical decision-making. The system will process images in real time and store data for subsequent analysis. AI outputs will be compared with physician assessment and reference standard histopathology to evaluate diagnostic performance.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Descrizione dettagliata

The artificial intelligence algorithms developed will be employed in the analysis of laryngeal lesions for 3 tasks:

  • Task 1: Computer aided diagnosis (CADx): the algorithm provides a differential diagnosis between benign and malignant neoplasms (binary classification) and the exact histology (multiclass classification). During the UADT video-endoscopy in the outpatient clinic, the physician performs the video-endoscopy and selects and captures n.3 WL and n.3 NBI significant frames of the lesion. The AI model records the classification output of the algorithm that the physician cannot access. The predicted pathologic results will be finally displayed as two different classifications along with the probability of each prediction (0% to 100%) as estimated by the AI algorithm: a first binary classification "neoplastic" or "non-neoplastic," and a second multiclass classification with the exact histology. The physician subsequently, based on the endoscopic examination, will write the suspected diagnosis (benign vs. malignant lesion and the actual histology) in the appropriate patient chart. Next, the physician reviews the screenshot taken and makes sure the lesion is visible in every one of them. Retrospectively, an investigator (blinded to the physician's assessment) will review the AI processed frames with the resulting CADx classifications and mark the AI-processed diagnosis in the patient chart. Once biopsied, the final histology of the lesion analyzed by definitive histopathological examination is recorded in the patient chart by the investigator. The investigators will finally compare the two recorded diagnoses (CADx and physician) with the definitive histology.
  • Task 2: Computer aided detection (CADe): the algorithm, through the representation of a rectangle (bounding box), localizes the lesion during the video-endoscopy in the outpatient clinic in real-time. During the UADT video-endoscopy, the physician performs the video-endoscopy as for standard-of-care procedure. In parallel, the AI model processes in real-time the endoscopic video and records the output of the algorithm (which the physician cannot access). The physician captures n.3 WL and n.3 NBI significant frames of the lesion. Moreover, n.3 frames where no lesions are visible are captured as negative controls. Later, the physician reviews the screenshot taken and makes sure to label the frames where the lesion is visible as "positive cases" and the frame where the lesion is not visible as "negative cases". The investigators will finally assess if the lesion was detected by the CADe system to define a "true positive". Similarly, to define a true negative, the CADe system should have not output a bounding box in the majority of the "negative cases" frames.
  • Task 3: Computer aided segmentation (CASe): the algorithm analyzes the neoplasm margins and provides a delineation mask. In the operating room setting, once the lesion to be resected is identified with a 0° telescope, the surgeon captures n.1 WL and n.1 NBI close-up photographs that exemplify the superficial lesion margins. The same procedure is repeated with a 70° optics and other two photographs are acquired. The frames taken are then saved and analyzed by the AI algorithm, which will perform the segmentation task. The surgeon will be blinded to the AI prediction. Later, the surgeon will draw the margins of the lesion according to her/his evaluation of each captured frame. The annotated frame will be saved so that it can be analyzed at a later time. Afterwards, in cases where positive superficial margins are identified by histopathologic examination, the surgeon-designed margins and the AI model ones will be compared to see if there was any difference in the suggested margin.

Tipo di studio

Osservativo

Iscrizione (Stimato)

283

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Belgio
    • Flemish Brabant
      • Leuven, Flemish Brabant, Belgio, 3000
        • UZ Leuven
        • Contatto:
        • Investigatore principale:
          • Vincent Vander Poorten, MD PhD
  • Italia
    • GE
      • Genova, GE, Italia, 16131
        • IRCCS Ospedale Policlinico San Martino
        • Contatto:
          • Francesco Mora, Otorhinolaryngologist and Prof
          • Numero di telefono: +39 010-5557479
          • Email: Francesco.Mora@unige.it
        • Investigatore principale:
          • Francesco Mora, MD PhD
  • Spagna
    • Barcelona
      • Barcelona, Barcelona, Spagna, 08036
        • Hospital Clinic De Barcelona
        • Contatto:
        • Investigatore principale:
          • Claudio Sampieri, MD PhD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The sample size for a single-arm, prospective cohort study, where the same group of patients undergoes testing with an AI model and a human physician and then they are compared with the gold standard reference test (biopsy) was calculated based on information from previous studies

Descrizione

Inclusion Criteria:

  • Age > 18 years
  • Injury originating from the upper aero-digestive tract
  • Recording of the video-endoscopic examination
  • Patient known to undergo a biopsy of the lesion or clinical follow-up for lesion with known biopsy (e.g. laryngeal papillomatosis) or suffering from Reinke's edema (in this pathology, in fact, biopsy is not necessary since the diagnosis is clinical)
  • Or patients undergoing transoral lesion excision

Exclusion Criteria:

  • Submucosal lesion
  • Patients with previous operations on the upper aero-digestive tract
  • Patients with previous radiotherapy of the head and neck district
  • Poor compliance on endoscopic examination
  • Unavailability of CADe/CADx or CASe data logging note

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Negative Predictive Value of the CADx Algorithm for Malignant or Premalignant Upper Aerodigestive Tract Lesions
Lasso di tempo: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
Negative Predictive Value (NPV) of the computer-aided diagnosis (CADx) algorithm for classifying UADT lesions as malignant/premalignant versus benign/non-neoplastic, using definitive histopathology as the reference standard. The CADx final classification will be based on the majority rule across selected white-light and narrow-band imaging frames. NPV = true negatives / (true negatives + false negatives). The pre-specified performance target is NPV ≥ 90%.
From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
Sensitivity of the CADe Algorithm for Localization of Upper Aerodigestive Tract Lesions
Lasso di tempo: At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.
Sensitivity of the computer-aided detection (CADe) algorithm for localizing UADT lesions with a bounding box. A true positive is defined as localization of the lesion area by a bounding box in the majority of physician-labeled lesion-positive captured frames. Sensitivity = true positives / (true positives + false negatives).
At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.
Median Intersection Over Union Between CASe Segmentation and Surgeon-Drawn Lesion Margins
Lasso di tempo: At intraoperative pre-resection endoscopy, with assessment performed after image annotation up to 30 days after surgery.
Median overlap between the AI-generated segmentation mask and the lesion margin area drawn by the surgeon on intraoperative endoscopic images. Intersection over Union (IoU) = area of overlap / area of union. Values range from 0 to 1; higher values indicate greater agreement.
At intraoperative pre-resection endoscopy, with assessment performed after image annotation up to 30 days after surgery.
Median Dice Similarity Coefficient Between CASe Segmentation and Surgeon-Drawn Lesion Margins
Lasso di tempo: At intraoperative pre-resection endoscopy, with assessment performed after image annotation up to 30 days after surgery.
Median Dice Similarity Coefficient (DSC) between the AI-generated segmentation mask and the lesion margin area drawn by the surgeon on intraoperative endoscopic images. Dice Similarity Coefficient = 2 × area of overlap / (AI segmented area + surgeon-drawn area). Values range from 0 to 1; higher values indicate greater agreement.
At intraoperative pre-resection endoscopy, with assessment performed after image annotation up to 30 days after surgery.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
WL-NPV vs. NBI-NPV of CADx classification
Lasso di tempo: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.

Negative Predictive Value (NPV) of CADx classification calculated using only the three selected white-light frames, compared with definitive histopathology, vs. NPV of CADx classification calculated using only the three selected narrow-band imaging frames, compared with definitive histopathology.

The final AI-result will be calculated based on the majority rule of the 3 WL and 3 NBI frames computed separately.
From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
Clinician-Reported Usability Score for the AI Endoscopy System
Lasso di tempo: Assessed after clinician use of the AI system during study procedures, up to 20 months after study initiation.
Usability of the AI endoscopy system assessed using standardized usability questionnaires administered to clinicians after use of the AI system. Questionnaire scoring will be interpreted according to the selected questionnaire manual, with higher scores indicating greater usability.
Assessed after clinician use of the AI system during study procedures, up to 20 months after study initiation.
Sensitivity, Specificity and Accuracy of CADx histology prediction
Lasso di tempo: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
Sensitivity, Specificity and Accuracy of the CADx algorithm for histology prediction, compared with definitive histopathology.
From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
F1 Score of CADx Classification
Lasso di tempo: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
F1 score of the CADx classification output compared with definitive histopathology.
From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
Area Under the Receiver Operating Characteristic Curve of CADx Classification
Lasso di tempo: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
AUC of the ROC curve for CADx classification of UADT lesions compared with definitive histopathology.
From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
Sensitivity, Specificity and Accuracy of human physician histology prediction
Lasso di tempo: From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
Sensitivity, Specificity an Accuracy of the treating physician's suspected diagnosis compared with definitive histopathology.
From index outpatient UADT video-endoscopy until definitive histopathology result is available, assessed up to 60 days after endoscopy.
Specificity of the CADe Algorithm for Localization of Upper Aerodigestive Tract Lesions
Lasso di tempo: At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.
Proportion of physician-labeled lesion-negative frames/cases in which the CADe algorithm does not output a bounding box in the majority of negative-control frames.
At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.
Accuracy of the CADe Algorithm for Localization of Upper Aerodigestive Tract Lesions
Lasso di tempo: At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.
Overall proportion of correctly classified lesion-positive and lesion-negative cases/frames by the CADe algorithm.
At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.
Positive Predictive Value of the CADe Algorithm for Localization of Upper Aerodigestive Tract Lesions
Lasso di tempo: At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.
Positive predictive value of CADe bounding-box output for lesion localization. PPV = true positives / (true positives + false positives).
At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.
Negative Predictive Value of the CADe Algorithm for Localization of Upper Aerodigestive Tract Lesions
Lasso di tempo: At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.
Negative predictive value of CADe absence of bounding-box output for lesion localization. NPV = true negatives / (true negatives + false negatives).
At index outpatient UADT video-endoscopy, with blinded post-processing assessment performed up to 30 days after endoscopy.
Percentage of Positive Superficial Margin Cases in Which the AI-Predicted Tumor Area Is Wider Than the Surgeon-Drawn Area
Lasso di tempo: At intraoperative pre-resection endoscopy, with assessment performed after image annotation up to 30 days after surgery.
Among cases with positive superficial margins on final histopathology, percentage of cases in which the AI-predicted tumor area extends beyond the surgeon-drawn margin at the affected margin.
At intraoperative pre-resection endoscopy, with assessment performed after image annotation up to 30 days after surgery.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Istituto Italiano di Tecnologia

Collaboratori

Universitaire Ziekenhuizen KU Leuven
Hospital Clinic of Barcelona
Universita degli Studi di Genova
CRO "Centro Clinical Trials" IRCCS Ospedale Policlinico San Martino
Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Scuola Superiore Sant'Anna di Pisa

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 maggio 2026

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 febbraio 2028

Date di iscrizione allo studio

Primo inviato

5 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 maggio 2026

Primo Inserito (Effettivo)

19 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • IIT_AIRCARE_H&NANCE

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Mauritania

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi